Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCTNASDAQ:GHRSNASDAQ:INCRNASDAQ:LVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$2.70+0.7%$2.41$1.05▼$4.13$265.80M1.9594,081 shs995,447 shsGHRSGH Research$12.72+4.3%$11.50$6.00▼$20.50$634.22M0.96194,465 shs575,106 shsINCRInterCure$1.48+0.7%$1.53$1.17▼$2.62$66.99M1.1925,916 shs23,279 shsLVTXLAVA Therapeutics$1.34+1.4%$1.30$0.85▼$2.39$34.72M0.48153,815 shs20,027 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics+0.37%-5.43%-12.90%+99.26%-26.63%GHRSGH Research+4.35%+1.44%+6.18%+22.31%+8.26%INCRInterCure+0.68%-1.99%-6.92%+7.64%-27.09%LVTXLAVA Therapeutics+1.44%+0.98%+2.21%+5.43%-28.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADCTADC Therapeutics1.6598 of 5 stars3.52.00.00.00.60.80.6GHRSGH Research1.6188 of 5 stars3.51.00.00.02.70.80.0INCRInterCure0.8999 of 5 stars0.05.00.00.02.00.00.6LVTXLAVA Therapeutics2.2749 of 5 stars3.05.00.00.03.30.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75187.04% UpsideGHRSGH Research 3.00Buy$32.00151.57% UpsideINCRInterCure 0.00N/AN/AN/ALVTXLAVA Therapeutics 2.00Hold$3.17136.49% UpsideCurrent Analyst Ratings BreakdownLatest ADCT, GHRS, INCR, and LVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025GHRSGH ResearchJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$39.006/20/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.006/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $10.006/4/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.005/15/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.005/15/2025LVTXLAVA TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/13/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025GHRSGH ResearchGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $29.005/9/2025GHRSGH ResearchHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$70.84M3.78N/AN/A($2.10) per share-1.29GHRSGH ResearchN/AN/AN/AN/A$3.44 per shareN/AINCRInterCure$64.55M1.04N/AN/A$2.36 per share0.63LVTXLAVA Therapeutics$11.98M2.94N/AN/A$1.06 per share1.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$157.85M-$1.45N/AN/AN/A-197.64%N/A-45.57%8/5/2025 (Estimated)GHRSGH Research-$38.96M-$0.79N/AN/AN/AN/A-19.20%-18.40%9/2/2025 (Estimated)INCRInterCure-$18.32MN/A0.00∞N/AN/AN/AN/A8/28/2025 (Estimated)LVTXLAVA Therapeutics-$25.11M-$1.04N/AN/AN/AN/A-86.38%-34.12%8/19/2025 (Estimated)Latest ADCT, GHRS, INCR, and LVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ADCTADC Therapeutics-$0.38-$0.36+$0.02-$0.36$17.71 million$23.03 million5/14/2025Q1 2025LVTXLAVA Therapeutics-$0.37-$0.13+$0.24-$0.13N/AN/A5/8/2025Q1 2025GHRSGH Research-$0.61-$0.19+$0.42-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.464.16GHRSGH ResearchN/A29.7129.71INCRInterCure0.341.731.18LVTXLAVA TherapeuticsN/A6.736.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%GHRSGH Research56.90%INCRInterCure8.34%LVTXLAVA TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%GHRSGH ResearchN/AINCRInterCureN/ALVTXLAVA Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics31099.18 million93.82 millionOptionableGHRSGH Research1052.03 millionN/AOptionableINCRInterCure35045.57 millionN/AOptionableLVTXLAVA Therapeutics6026.31 million23.81 millionOptionableADCT, GHRS, INCR, and LVTX HeadlinesRecent News About These CompaniesLAVA Therapeutics Shareholders Approve Key Proposals in MeetingJune 13, 2025 | tipranks.comHere's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn SituationMay 16, 2025 | finance.yahoo.comLAVA Therapeutics N.V.: LAVA Reports First Quarter 2025 Financial Results, Provides Business UpdateMay 15, 2025 | finanznachrichten.deLAVA Reports First Quarter 2025 Financial Results, Provides Business UpdateMay 14, 2025 | globenewswire.comLAVA Therapeutics Granted Full Waiver for RVO Payment Obligation | LVTX Stock NewsApril 16, 2025 | gurufocus.comLAVA Therapeutics Strengthens Balance Sheet with $5.1 Million Repayment Waiver from Netherlands Enterprise AgencyApril 16, 2025 | quiverquant.comQLAVA Therapeutics (LVTX) Secures $5.1 Million Debt Waiver from Netherlands Enterprise Agency | ...April 16, 2025 | gurufocus.comLAVA Therapeutics Granted Full Waiver for RVO Payment ObligationApril 16, 2025 | globenewswire.comLava Therapeutics reports Q4 EPS (14c) vs. (24c) last yearMarch 29, 2025 | markets.businessinsider.comLAVA Therapeutics GAAP EPS of -$0.14, revenue of $4.99MMarch 28, 2025 | seekingalpha.comLAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateMarch 28, 2025 | globenewswire.comAnalyst Downgrades LAVA Therapeutics, Sees Pipeline OverhangFebruary 28, 2025 | benzinga.comCautious Stance on LAVA Therapeutics Amid Strategic Review and Workforce ReductionFebruary 27, 2025 | tipranks.comLava Therapeutics announces evaluation of strategic optionsFebruary 26, 2025 | markets.businessinsider.comLAVA Therapeutics (NASDAQ:LVTX) Stock Quotes, Forecast and News SummaryFebruary 26, 2025 | benzinga.comLava Therapeutics trims workforce by 30% to preserve cashFebruary 25, 2025 | bizjournals.comSerina Therapeutics Appoints Karen J. Wilson to Board of DirectorsJanuary 14, 2025 | quiverquant.comQLAVA Therapeutics Doses First Patient in Phase 1 Study of Bispecific Gammabody® LAVA-1266 for CD123-Expressing Blood CancersJanuary 10, 2025 | quiverquant.comQLAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological CancersJanuary 10, 2025 | globenewswire.comLAVA Therapeutics to Transition to U.S. Domestic IssuerJanuary 2, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI SpendingNew Catalysts to Drive NVIDIA’s Stock Price Even HigherBy Thomas Hughes | June 16, 2025View New Catalysts to Drive NVIDIA’s Stock Price Even HigherMarvell's New AI Chip Deals Capture Wall Street’s AttentionBy Jeffrey Neal Johnson | June 21, 2025View Marvell's New AI Chip Deals Capture Wall Street’s AttentionSalesforce Raises Prices: 3 Reasons Its Stock Price Will FollowBy Thomas Hughes | June 18, 2025View Salesforce Raises Prices: 3 Reasons Its Stock Price Will FollowAppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target AnywayBy Leo Miller | June 10, 2025View AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target AnywayADCT, GHRS, INCR, and LVTX Company DescriptionsADC Therapeutics NYSE:ADCT$2.70 +0.02 (+0.75%) Closing price 07/1/2025 03:59 PM EasternExtended Trading$2.71 +0.01 (+0.37%) As of 06:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.GH Research NASDAQ:GHRS$12.72 +0.53 (+4.35%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$12.74 +0.01 (+0.12%) As of 07/1/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.InterCure NASDAQ:INCR$1.48 +0.01 (+0.68%) Closing price 07/1/2025 03:48 PM EasternExtended Trading$1.40 -0.08 (-5.07%) As of 07/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.LAVA Therapeutics NASDAQ:LVTX$1.34 +0.02 (+1.44%) Closing price 07/1/2025 03:57 PM EasternExtended Trading$1.34 0.00 (-0.30%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
